Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Pharmacokinetics

Tacrolimus clearance is age-dependent within the pediatric population

Bone Marrow Transplantation volume 26, pages 601–605 (2000)Cite this article

Abstract

for prevention of graft-versus-host disease, the consensus initial intravenous dose of tacrolimus for adults is 0.03 mg/kg/day. whether target whole blood concentrations of tacrolimus in children undergoing hematopoietic stem cell transplantation can be achieved reproducibly with this dose is not known. we reviewed the tacrolimus blood levels and calculated clearances for 55 children (aged 6 months to 18 years, median 9 years) using tacrolimus after allogeneic marrow, blood stem cell or cord blood transplantation. the tacrolimus dose regimen was 0.03 mg/kg/day by continuous infusion starting on day −1 or day −2. at the first sampling in the peritransplant period, 71% of the tacrolimus blood levels were within the target range of 5–15 ng/ml, 87% were in the safe range of 5–20 ng/ml, 9% were toxic, and 4% were subtherapeutic. twenty-five children were converted to oral drug using the recommended oral/intravenous dose ratio of 4.0. at the first sampling after oral conversion, 80% were in the target range, and 20% were subtherapeutic. clearance of tacrolimus was calculated from the blood levels for patients during intravenous dosing and normalized by ideal body weight. there was a decreased clearance over the first 2 weeks only for the children >12 years old (P = 0.014). The initial calculated clearances of tacrolimus did not differ between age groups, but at steady state the mean tacrolimus clearance (± s.d.) was higher for those <6 years old (0.159 ± 0.082 l/h/kg) than for those 6–12 years old (0.109 ± 0.053 l/h/kg) or >12 years old (0.104 ± 0.068 l/h/kg). Children <6 years old undergoing hematopoietic stem cell transplantation have a higher weight-normalized tacrolimus clearance than older children and adults, and careful therapeutic monitoring is needed in the first 2 weeks after transplantation to avoid prolonged subtherapeutic dosing for this age group. Bone Marrow Transplantation (2000) 26, 601–605.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Ratanatharathorn V, Nash RA, Przepiorka D et al. Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation Blood 1998 92: 2303–2314

    CAS  PubMed  Google Scholar 

  2. Nash RA, Antin JH, Karanes C et al. A phase III study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors Blood 1997 90: 561a (Abstr. 2499)

    Google Scholar 

  3. Hiraoka AF for the Japanese FK506 BMT Study Group . Results of a phase III study on prophylactic use of FK506 for acute GVHD compared with cyclosporine in allogeneic bone marrow transplantation Blood 1997 90: 561a (Abstr. 2500)

    Google Scholar 

  4. Przepiorka D, Devine SM, Fay JW et al. Practical considerations in the use of tacrolimus for allogeneic marrow transplantation Bone Marrow Transplant 1999 24: 1053–1056

    Article  CAS  Google Scholar 

  5. Koehler MT, Howrie D, Mirro J et al. FK506 (tacrolimus) in the treatment of steroid-resistant acute graft-versus-host disease in children undergoing bone marrow transplantation Bone Marrow Transplant 1995 15: 895–899

    CAS  PubMed  Google Scholar 

  6. Przepiorka D, Petropoulos D, Mullen CA et al. Tacrolimus for prevention of graft-versus-host disease after mismatched unrelated donor cord blood transplantation Bone Marrow Transplant 1999 23: 1291–1295

    Article  CAS  Google Scholar 

  7. Worth LL, Tran H, Petropoulos D et al. Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide Bone Marrow Transplant 1999 24: 947–952

    Article  CAS  Google Scholar 

  8. Jain AB, Fung JJ, Tzakis AG et al. Comparative study of cyclosporine and FK506 dosage requirements in adult and pediatric orthotopic liver transplant patients Transplant Proc 1991 23: 2763–2766

    CAS  PubMed  PubMed Central  Google Scholar 

  9. McDiarmid SV, Colonna JO, Shaked A et al. Differences in oral FK506 dose requirements between adult and pediatric liver transplant patients Transplantation 1993 55: 1328–1332

    Article  CAS  Google Scholar 

  10. Robinson BV, Boyle GJ, Miller SA et al. Optimal dosing of intravenous tacrolimus following pediatric heart transplantation J Heart Lung Transplant 1999 18: 786–791

    Article  CAS  Google Scholar 

  11. Yasuhara M, Hashida T, Toraguchi M et al. Pharmacokinetics and pharmacodynamics of FK506 in pediatric patients receiving living-related donor liver transplantations Transplant Proc 1995 27: 1108–1110

    CAS  PubMed  Google Scholar 

  12. Wallemacq PE, Furlan V, Moller A et al. Pharmacokinetics of tacrolimus (FK506) in pediatric liver transplant recipients Eur J Drug Metab Pharmacokinet 1998 23: 367–370

    Article  CAS  Google Scholar 

  13. Grenier FC, Luczkiw J, Bergmann M et al. A whole blood FK506 assay for the IMx analyzer Transplant Proc 1991 23: 2748–2749

    CAS  PubMed  Google Scholar 

  14. Mehta P, Beltz S, Kedar A et al. Increased clearance of tacrolimus in children: need for higher doses and earlier initiation prior to bone marrow transplantation Bone Marrow Transplant 1999 24: 1323–1327

    Article  CAS  Google Scholar 

  15. Boswell GW, Bekersky I, Fay J et al. Tacrolimus pharmacokinetics in BMT patients Bone Marrow Transplant 1998 21: 23–28

    Article  CAS  Google Scholar 

  16. Spencer CM, Goa KL, Gillis JC . Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation Drugs 1997 54: 925–975

    Article  CAS  Google Scholar 

  17. Tanaka E . In vivo age-related changes in hepatic drug-oxidizing capacity in humans J Clin Pharm Ther 1998 23: 247–255

    Article  CAS  Google Scholar 

  18. Murry DJ, Crom WR, Reddick WE et al. Liver volume as a determinant of drug clearance in children and adolescents Drug Metab Dispos 1995 23: 1110–1116

    CAS  PubMed  Google Scholar 

  19. Wingard JR, Nash RA, Przepiorka D et al. Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation Biol Blood Marrow Transplant 1998 4: 157–163

    Article  CAS  Google Scholar 

  20. Przepiorka D, Nash RA, Wingard JR et al. Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor marrow transplantation Biol Blood Marrow Transplant 1999 5: 94–97

    Article  CAS  Google Scholar 

  21. Przepiorka D, Saliba R, Cleary K et al. Tacrolimus does not abrogate the increased risk of acute graft-vs-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1 Biol Blood Marrow Transplant 2000 6: 190–197

    Article  CAS  Google Scholar 

  22. Przepiorka D, Ippoliti C, Khouri I et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation Blood 1996 88: 4383–4389

    CAS  PubMed  Google Scholar 

  23. Woo MH, Przepiorka D, Ippoliti C et al. Toxicities of tacrolimus and cyclosporine after allogeneic blood stem cell transplantation Bone Marrow Transplant 1997 20: 1095–1098

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Baylor College of Medicine Center for Cell and Gene Therapy, Houston, USA

    D Przepiorka & R Krance

  2. Texas Childrens’ Hospital, Houston, USA

    D Przepiorka & R Krance

  3. Department of Clinical Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

    D Blamble & M Danielson

  4. Baylor College of Medicine Section of Hematology/Oncology, Houston, USA

    S Hilsenbeck

  5. Department of Clinical Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

    KW Chan

Authors
  1. D Przepiorka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D Blamble
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Hilsenbeck
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Danielson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Krance
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. KW Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Przepiorka, D., Blamble, D., Hilsenbeck, S. et al. Tacrolimus clearance is age-dependent within the pediatric population. Bone Marrow Transplant 26, 601–605 (2000). https://doi.org/10.1038/sj.bmt.1702588

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702588

Keywords

This article is cited by

Search

Advanced search

Quick links